Imatinib
B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)
The University of Hong KongSmall moleculePhase 3Active
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
30 Active assets in the B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nilotinib The University of Hong Kong | Phase 2 | BBB |
Cytarabine Novartis Pharmaceuticals | Phase 3 | BBB |
Blinatumomab Novartis Pharmaceuticals | Phase 3 | BBB |
Methotrexate Novartis Pharmaceuticals | Phase 3 | BB |
Dasatinib SWOG Cancer Research Network | Phase 3 | BB |
View all 47 →
Same molecule, other indications
Imatinib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveActive
BB
Indicative · Phase 2
71 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →